tbuckley/cabot-search huggingface dataset:
A comment to “efficacy of surgical intervention over conservative management in intertrochanteric fractures among nonagenarians and centenarians: a prospective cohort study”
Authors: Jiaan Lu, Guanhu Yang, Hao Chi, Qinglai Wang
Journal: International Journal of Surgery (2024)

aSchool of Clinical Medicine, The Affiliated Hospital, Southwest Medical University, Luzhou 646000,Sichuan, P. R. China bOrthopedics and Traumatology Department of TCM, Wenzhou TCM Hospital of Zhejiang Chinese Medical University, Wenzhou 325000, China cDepartment of Specialty Medicine, Ohio University, Athens 45701, OH, United States Jiaan Lu, Guanhu Yang and Hao Chi: These authors have contributed equally to this work. Sponsorships or competing interests that may be relevant to content are disclosed at the end of this article. Published online ■ ■ *Corresponding author. Address: Orthopedics and Traumatology Department of TCM, Wenzhou TCM Hospital of Zhejiang Chinese Medical University, Wenzhou 325000, China. E-mail address: [email protected] (Q. Wang). This is an open access article distributed under the Creative Commons Attribution-ShareAlike License 4.0, which allows others to remix, tweak, and build upon the work, even for commercial purposes, as long as the author is credited and the new creations are licensed under the identical terms. http://creativecommons.org/licenses/by-sa/4.0/
Unilateral biportal Endo-LIF facilitates the recovery of an elderly patient with lumbar stenosis with degenerative spinal scoliosis
Authors: Changjun Chen, Qingwei Ma, Lei Zhang
Journal: International Journal of Surgery (2024)

Department of Orthopedic Surgery, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Shandong Key Laboratory of Rheumatic Disease and Translational Medicine, Jinan, China Changjun Chen and Qingwei Ma contributed equally to this work. Sponsorships or competing interests that may be relevant to content are disclosed at the end of this article. Published online ■ ■ *Corresponding author. Address: Department of Orthopedic Surgery, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Shandong Key Laboratory of Rheumatic Disease and Translational Medicine, Jinan, China: +86 053189269860. E-mail address: [email protected] (C. Chen). *Corresponding author. Address: Department of Orthopedic Surgery, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Shandong Key Laboratory of Rheumatic Disease and Translational Medicine, Jinan, China : +86 053189269860. E-mail address: [email protected] (L. Zhang). This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms. http://creativecommons.org/licenses/by-nc-sa/4.0/
Cystic Plate Approach Combined with Indocyanine Green（ICG） Fluorescence in Laparoscopic Anatomical Hepatectomy
Authors: Hao Chen, Kefeng Shen, Xiayong Shen, Wenbin Liu, Yongsheng Ge, Jihai Yu, Weidong Jia, Jinliang Ma, Peng Yuan, Chuanhai Zhang
Journal: International Journal of Surgery (2024)

Background: The in-depth understanding of the fine anatomy of the liver has promoted the development of modern liver surgery. With the rapid popularity of laparoscopic hepatectomy, the membrane structure of the liver and its ability to dissect the intrahepatic and extrahepatic vascular system more conveniently and accurately has been gradually emphasized. Objective: Exploring the value of extrahepatic sheath dissection of the hepatic pedicle in minimally invasive anatomical hepatectomy with cystic plate approach. This study aims to assess the benefits of integrating the cystic plate approach with real-time guided laparoscopic anatomical hepatectomy, in comparison with conventional laparoscopic anatomical hepatectomy. Materials and methods: Based on the theory of cystic plate and hepatic portal plate, the authors have pioneered the fluorescence real-time guided cystic plate approach in hepatectomy. The article focuses on the anatomical knowledge and technical difficulties of anatomical hepatectomy with fluoroscopic laparoscopic cystic plate approach and explores the safety and practicality of the cystic plate approach in laparoscopic anatomical hepatectomy. Additionally, a retrospective cohort study was also conducted to compare the operation time, intraoperative blood loss, and postoperative complications between the cystic plate approach and the conventional approach during fluoroscopic laparoscopic hepatectomy. Results: A total of 38 patients who met the inclusion criteria underwent laparoscopic hepatectomy between January 2019 and November 2022. No significant disadvantages were found in terms of operation time and intraoperative blood loss during the surgeries. Furthermore, the postoperative indications, including liver function indexes on the first postoperative day, WBC, and the postoperative hospital stay, were also not affected, thus proving the safety of the cystic approach. Importantly, through the cystic plate approach, the target liver pedicle was fully freed, and then the segments to be resected were precisely marked by positive or negative staining, followed by hepatectomy under real-time fluoroscopic guidance. This approach is extremely advantageous in anatomical liver segment resections, especially in right posterior lobe or hemi-hepatectomy, without increasing intraoperative bleeding or postoperative complication rates. Conclusion: This technique allows for easy and safe freeing of the target liver pedicle using membrane structures, and also allows for precise anatomical hepatectomy in combination with real-time fluoroscopic laparoscopic navigation.
A commentary on “Causal effects of gut microbiota on renal tumor: a mendelian randomization study”
Authors: Xingcheng Zhu, Qiuyu Mao, Junxian Zhao, Peiqin Zhan, Zhengyan Wang, Tianci Gao, Hongping Bao
Journal: International Journal of Surgery (2024)

Zhu, Xingcheng; Mao, Qiuyu; Zhao, Junxian; Zhan, Peiqin; Wang, Zhengyan; Gao, Tianci; Bao, Hongping Author Information
Comment on ‘exploring the complex relationship between vitamin K, gut microbiota, and warfarin variability in cardiac surgery patients’
Authors: Zhiling Zhou, Chaoying Jiang, Yu Ren
Journal: International Journal of Surgery (2024)

aDepartment of Medicine, Wenzhou Medical University bDepartment of Orthopedic, Taizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical University cDepartment of Pharmacy, Taizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical University, Taizhou, Zhejiang, China Z.Z. and C.J. have contributed equally to this work and share first authorship. Sponsorships or competing interests that may be relevant to content are disclosed at the end of this article. Published online ■ ■ *Corresponding author. Address: Department of Pharmacy, Taizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical University, No.150 Ximen Road, Taizhou 317000, Zhejiang, China. Tel.: +86 13073647921. E-mail address: [email protected] (Y. Ren). This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0/
Comment on “Development and validation of models for predicting mortality in intertrochanteric fracture surgery patients with perioperative blood transfusion: a prospective multicenter cohort study”
Authors: Hui Liu, Jinhui Zhang, Jin Wu
Journal: International Journal of Surgery (2024)

Department of Orthopaedics, the 909th Hospital, School of Medicine, Xiamen University, Fujian, China Running Title: intertrochanteric fracture surgery and perioperative blood transfusion. Sponsorships or competing interests that may be relevant to content are disclosed at the end of this article. Published online ■ ■ *Corresponding author. Address: Department of Orthopaedics, the 909th Hospital, School of Medicine, Xiamen University, Fujian, China. E-mail address: [email protected] (J. Wu). This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0/
State-Specific Hepatitis C Virus Clearance Cascades — United States, 2013–2022
Authors: Clarisse A. Tsang, Julius Tonzel, Hasan Symum, Harvey W. Kaufman, William A. Meyer, Ademola Osinubi, William W. Thompson, Carolyn Wester
Journal: MMWR Morbidity and Mortality Weekly Report (2024)

Hepatitis C is a deadly, yet curable, disease.National hepatitis C elimination goals for 2030 call for at least 80% of persons with hepatitis C to achieve viral clearance.A welltolerated treatment results in sustained viral clearance in ≥95% of cases.Hepatitis C virus (HCV) clearance cascades characterize a sequence of steps that follow the progression from testing to sustained viral clearance.Monitoring HCV clearance cascades is important for tracking progress toward elimination goals and identifying gaps in diagnosis, treatment, and prevention.State-specific HCV clearance cascades based on laboratory results were developed using longitudinal data from a large national, commercial laboratory during January 1, 2013-December 31, 2022.State-level estimates of viral testing among persons with evidence of past or current HCV infection ranged from 51% (Hawaii) to 99% (South Dakota), and hepatitis C viral clearance among persons with diagnosed HCV infection ranged from 10% (West Virginia) to 51% (Connecticut).These are the first state-level estimates using CDC guidance and data from a large commercial laboratory with national coverage to generate HCV clearance cascades.These estimates reveal substantial gaps in hepatitis C diagnosis, treatment, and prevention and can help guide prioritization of activities and resources to achieve hepatitis C elimination goals.
West Nile Virus and Other Nationally Notifiable Arboviral Diseases — United States, 2022
Authors: Rebekah A. Sutter, Shelby Lyons, Carolyn V. Gould, J. Erin Staples, Nicole P. Lindsey
Journal: MMWR Morbidity and Mortality Weekly Report (2024)

Arthropodborne viruses (arboviruses) primarily infect humans through the bite of an infected mosquito or tick.Infections are commonly asymptomatic; however, the clinical signs and symptoms can range from a mild febrile illness to severe neuroinvasive disease.This report summarizes data for six nationally notifiable arboviral diseases for 2022 reported to ArboNET, the national surveillance system for arboviral diseases, including eastern equine encephalitis, Jamestown Canyon, La Crosse, Powassan, St. Louis encephalitis, and West Nile viruses.In 2022, these viruses caused 1,247 human disease cases, 968 (78%) hospitalizations, and 103 (8%) deaths.Reported case counts decreased from 2021 for all viruses except Powassan and St. Louis encephalitis viruses.Despite a substantial decrease in reported cases from 2021, West Nile virus remained the leading cause of arboviral disease in the continental United States.Variations in annual arboviral disease incidence and distribution highlight the importance of high-quality surveillance.Health care providers should suspect arboviral infection in patients with a clinically compatible illness, consider testing, and report positive findings to their state or local health department.In areas with arboviral activity, community and household efforts to reduce vector populations (e.g., applying insecticides and reducing breeding sites) and personal protective measures to decrease mosquito and tick exposures (e.g., wearing repellents and protective clothing) can reduce arboviral disease morbidity and mortality.
Early Safety Findings Among Persons Aged ≥60 Years Who Received a Respiratory Syncytial Virus Vaccine — United States, May 3, 2023–April 14, 2024
Authors: Anne M. Hause, Pedro L. Moro, James Baggs, Bicheng Zhang, Paige Marquez, Michael Melgar, Amadea Britton, Erin Stroud, Tanya R. Myers, Jeffrey Rakickas, Phillip G. Blanc, Kerry Welsh, Karen R. Broder, John R. Su, David K. Shay
Journal: MMWR Morbidity and Mortality Weekly Report (2024)

In May 2023, the Food and Drug Administration (FDA) licensed Arexvy and Abrysvo vaccines for prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in adults aged ≥60 years.In prelicensure trials, Guillain-Barré syndrome (GBS) was identified as a potential safety concern.During August 4, 2023-March 30, 2024, at least 10.6 million adults aged ≥60 years received a recommended RSV vaccine.During May 3, 2023-April 14, 2024, CDC reviewed data reported after RSV vaccination to V-safe, an active U.S. surveillance system that invites enrolled participants to complete web-based surveys, and reports to the Vaccine Adverse Event Reporting System (VAERS), a passive, voluntary surveillance system that accepts adverse event reports from the public, providers, and manufacturers.Findings from V-safe and VAERS were generally consistent with those from trials.Reporting rates of GBS after RSV vaccination in VAERS (5.0 and 1.5 reports per million doses of Abrysvo and Arexvy vaccine administered, respectively) were higher than estimated expected background rates in a vaccinated population.CDC and FDA are conducting population-based surveillance to assess risks for GBS and other adverse events.Findings from these studies will help guide development of Advisory Committee on Immunization Practices recommendations.
Alternative platelet differentiation pathways initiated by nonhierarchically related hematopoietic stem cells
Authors: Joana Carrelha, Stefania Mazzi, Axel Winroth, Michael Hagemann-Jensen, Christoph Ziegenhain, Kari Högstrand, Masafumi Seki, Margs S. Brennan, Madeleine Lehander, Bishan Wu, Yiran Meng, Ellen Markljung, Ruggiero Norfo, Hisashi Ishida, Karin Belander Strålin, Francesca Grasso, Christina Simoglou Karali, Affaf Aliouat, Amy Hillen, Edwin Chari, Kimberly Siletti, Supat Thongjuea, Adam J. Mead, Sten Linnarsson, Claus Nerlov, Rickard Sandberg, Tetsuichi Yoshizato, Petter S. Woll, Sten Eirik W. Jacobsen
Journal: Nature Immunology (2024)

Abstract Rare multipotent stem cells replenish millions of blood cells per second through a time-consuming process, passing through multiple stages of increasingly lineage-restricted progenitors. Although insults to the blood-forming system highlight the need for more rapid blood replenishment from stem cells, established models of hematopoiesis implicate only one mandatory differentiation pathway for each blood cell lineage. Here, we establish a nonhierarchical relationship between distinct stem cells that replenish all blood cell lineages and stem cells that replenish almost exclusively platelets, a lineage essential for hemostasis and with important roles in both the innate and adaptive immune systems. These distinct stem cells use cellularly, molecularly and functionally separate pathways for the replenishment of molecularly distinct megakaryocyte-restricted progenitors: a slower steady-state multipotent pathway and a fast-track emergency-activated platelet-restricted pathway. These findings provide a framework for enhancing platelet replenishment in settings in which slow recovery of platelets remains a major clinical challenge.
The evolving landscape of tissue‐agnostic therapies in precision oncology
Authors: Vivek Subbiah, Mohamed A. Gouda, Bettina Ryll, Howard A. Burris, Razelle Kurzrock
Journal: CA A Cancer Journal for Clinicians (2024)

Tumor-agnostic therapies represent a paradigm shift in oncology by altering the traditional means of characterizing tumors based on their origin or location. Instead, they zero in on specific genetic anomalies responsible for fueling malignant growth. The watershed moment for tumor-agnostic therapies arrived in 2017, with the US Food and Drug Administration's historic approval of pembrolizumab, an immune checkpoint inhibitor. This milestone marked the marriage of genomics and immunology fields, as an immunotherapeutic agent gained approval based on genomic biomarkers, specifically, microsatellite instability-high or mismatch repair deficiency (dMMR). Subsequently, the approval of NTRK inhibitors, designed to combat NTRK gene fusions prevalent in various tumor types, including pediatric cancers and adult solid tumors, further underscored the potential of tumor-agnostic therapies. The US Food and Drug Administration approvals of targeted therapies (BRAF V600E, RET fusion), immunotherapies (tumor mutational burden ≥10 mutations per megabase, dMMR) and an antibody-drug conjugate (Her2-positive-immunohistochemistry 3+ expression) with pan-cancer efficacy have continued, offering newfound hope to patients grappling with advanced solid tumors that harbor particular biomarkers. In this comprehensive review, the authors delve into the expansive landscape of tissue-agnostic targets and drugs, shedding light on the rationale underpinning this approach, the hurdles it faces, presently approved therapies, voices from the patient advocacy perspective, and the tantalizing prospects on the horizon. This is a welcome advance in oncology that transcends the boundaries of histology and location to provide personalized options.
Biomaterial‐Based Therapeutic Delivery of Immune Cells
Authors: Ameya A. Dravid, Ankur Singh, Andrés J. García
Journal: Advanced Healthcare Materials (2024)

Abstract Immune cell therapy (ICT) is a transformative approach used to treat a wide range of diseases including type 1 diabetes, sickle cell disease, disorders of the hematopoietic system, and certain forms of cancers. Despite excellent clinical successes, the scope of adoptively transferred immune cells is limited because of toxicities like cytokine release syndrome and immune effector cell‐associated neurotoxicity in patients. Furthermore, reports suggest that such treatment can impact major organ systems including cardiac, renal, pulmonary, and hepatic systems in the long term. Additionally, adoptively transferred immune cells cannot achieve significant penetration into solid tissues, thus limiting their therapeutic potential. Recent studies suggest that biomaterial‐assisted delivery of immune cells can address these challenges by reducing toxicity, improving localization, and maintaining desired phenotypes to eventually regain tissue function. In this review, recent efforts in the field of biomaterial‐based immune cell delivery for the treatment of diseases, their pros and cons, and where these approaches stand in terms of clinical treatment are highlighted.
Targeting nanoplatform synergistic glutathione depletion-enhanced chemodynamic, microwave dynamic, and selective-microwave thermal to treat lung cancer bone metastasis
Authors: Man Shu, Jingguang Wang, Ziyang Xu, Teliang Lu, Yue He, Renshan Li, Guoqing Zhong, Yunbo Yan, Yu Zhang, Xiao Chu, Jin Ke
Journal: Bioactive Materials (2024)

Once bone metastasis occurs in lung cancer, the efficiency of treatment can be greatly reduced. Current mainstream treatments are focused on inhibiting cancer cell growth and preventing bone destruction. Microwave ablation (MWA) has been used to treat bone tumors. However, MWA may damage the surrounding normal tissues. Therefore, it could be beneficial to develop a nanocarrier combined with microwave to treat bone metastasis. Herein, a microwave-responsive nanoplatform (MgFe
Functional biomaterials for modulating the dysfunctional pathological microenvironment of spinal cord injury
Authors: Dezun Ma, Changlong Fu, Fenglu Li, Renjie Ruan, Yanming Lin, Xihai Li, Min Li, Jin Zhang
Journal: Bioactive Materials (2024)

Spinal cord injury (SCI) often results in irreversible loss of sensory and motor functions, and most SCIs are incurable with current medical practice. One of the hardest challenges in treating SCI is the development of a dysfunctional pathological microenvironment, which mainly comprises excessive inflammation, deposition of inhibitory molecules, neurotrophic factor deprivation, glial scar formation, and imbalance of vascular function. To overcome this challenge, implantation of functional biomaterials at the injury site has been regarded as a potential treatment for modulating the dysfunctional microenvironment to support axon regeneration, remyelination at injury site, and functional recovery after SCI. This review summarizes characteristics of dysfunctional pathological microenvironment and recent advances in biomaterials as well as the technologies used to modulate inflammatory microenvironment, regulate inhibitory microenvironment, and reshape revascularization microenvironment. Moreover, technological limitations, challenges, and future prospects of functional biomaterials to promote efficient repair of SCI are also discussed. This review will aid further understanding and development of functional biomaterials to regulate pathological SCI microenvironment.
Biodegradable PMMA coated Zn–Mg alloy with bimodal grain structure for orthopedic applications - A promising alternative
Authors: Alia A. Diaa, Nahed El-Mahallawy, Madiha Shoeib, Flavien Mouillard, Tom Ferté, Patrick Masson, Adele Carradò
Journal: Bioactive Materials (2024)

The study examines the impact of microstructure and polymethyl methacrylate (PMMA) grafting on the degradability of Zn-Mg alloys. The mechanical properties of a Zn alloy containing 0.68 wt% Mg and extruded at 200 °C are enhanced for degradable load-bearing applications, addressing a crucial need in the field. The material exhibits a bimodal grain size distribution that is random texture, consisting of secondary phases, grains, and sub-grains. With an elongation to failure of 16 %, the yield and ultimate tensile strengths are 325.9 and 414.5 MPa, respectively, and the compressive yield strength is 450.5 MPa. The "grafting-from" method was used to coat a few micrometers thick of PMMA on both bulk and scaffold Zn alloys to mitigate the corrosion rate. The last one is a porous structure, with a porosity of 65.8 %, considered as in the first approach of an orthopedic implant. After being immersed for 720 h, the PMMA-grafted bulk alloy's corrosion rate decreased from 0.43 to 0.25 mm/y. Similarly, the scaffold alloy's corrosion rate reduced from 1.24 to 0.49 mm/y. These results indicate that the method employed could be used for future orthopedic applications.